4//SEC Filing
Silva Paul M 4
Accession 0001209191-21-015849
CIK 0000875320other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:07 PM ET
Size
12.8 KB
Accession
0001209191-21-015849
Insider Transaction Report
Form 4
Silva Paul M
V.P. and Corporate Controller
Transactions
- Tax Payment
Common Stock
2021-02-26$212.42/sh−2,218$471,148→ 12,666 total - Sale
Common Stock
2021-03-01$211.45/sh−610$128,985→ 11,030 total - Sale
Common Stock
2021-03-01$213.12/sh−231$49,231→ 9,884 total - Sale
Common Stock
2021-03-01$210.13/sh−1,026$215,593→ 11,640 total - Sale
Common Stock
2021-03-01$212.51/sh−915$194,447→ 10,115 total
Holdings
- 169(indirect: By 401(k))
Common Stock
Footnotes (6)
- [F1]Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
- [F3]Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
- [F5]Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
- [F6]Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001446372
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 4:07 PM ET
- Size
- 12.8 KB